156 related articles for article (PubMed ID: 27199521)
1. Adjuvant chemotherapy for early-stage cervical cancer.
Asano H; Todo Y; Watari H
Chin J Cancer Res; 2016 Apr; 28(2):228-34. PubMed ID: 27199521
[TBL] [Abstract][Full Text] [Related]
2. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
[TBL] [Abstract][Full Text] [Related]
4. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy.
Hosaka M; Watari H; Kato T; Odagiri T; Konno Y; Endo D; Mitamura T; Kikawa S; Suzuki Y; Sakuragi N
J Surg Oncol; 2012 May; 105(6):612-6. PubMed ID: 22065519
[TBL] [Abstract][Full Text] [Related]
6. The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.
Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Obstet Gynaecol Res; 2017 Apr; 43(4):617-626. PubMed ID: 28190285
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).
Nakamura K; Kitahara Y; Satoh T; Takei Y; Takano M; Nagao S; Sekiguchi I; Suzuki M
World J Surg Oncol; 2016 Jun; 14(1):173. PubMed ID: 27356862
[TBL] [Abstract][Full Text] [Related]
8. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
9. Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: A single-institutional retrospective study from a prospective database.
Liu B; Li L; Wang M; Wei L; Li J; Zou W; Lv Y; Zhang H; Liu S
Gynecol Oncol; 2019 Sep; 154(3):583-589. PubMed ID: 31307665
[TBL] [Abstract][Full Text] [Related]
10. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.
Song S; Song C; Kim HJ; Wu HG; Kim JH; Park NH; Song YS; Kim JW; Kang SB; Ha SW
Gynecol Oncol; 2012 Jan; 124(1):63-7. PubMed ID: 22004904
[TBL] [Abstract][Full Text] [Related]
11. CLPTM1L expression predicts recurrence of patients with intermediate‑ and high‑risk stage IB‑IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy.
Awazu Y; Fukuda T; Noda T; Uchikura E; Nanno S; Imai K; Yamauchi M; Yasui T; Sumi T
Oncol Lett; 2023 Aug; 26(2):353. PubMed ID: 37545614
[TBL] [Abstract][Full Text] [Related]
12. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.
Mabuchi S; Morishige K; Isohashi F; Yoshioka Y; Takeda T; Yamamoto T; Yoshino K; Enomoto T; Inoue T; Kimura T
Gynecol Oncol; 2009 Dec; 115(3):482-7. PubMed ID: 19783286
[TBL] [Abstract][Full Text] [Related]
13. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
14. Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy achieved the equivalent survival compared with concurrent chemoradiotherapy in cervical cancer patients with intermediate-risk.
Yu H; Zhang L; Li D; Liu N; Yin Y; Zhang L; Yuan L; Liu M; Sheng X
Jpn J Clin Oncol; 2019 Aug; 49(8):714-718. PubMed ID: 31329905
[TBL] [Abstract][Full Text] [Related]
15. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
[TBL] [Abstract][Full Text] [Related]
17. Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.
Ikeda Y; Furusawa A; Kitagawa R; Tokinaga A; Ito F; Ukita M; Nomura H; Yamagami W; Tanabe H; Mikami M; Takeshima N; Yaegashi N
J Gynecol Oncol; 2016 May; 27(3):e29. PubMed ID: 27029750
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy for cervical carcinoma - current status.
Serkies K; Jassem J
Chin J Cancer Res; 2018 Apr; 30(2):209-221. PubMed ID: 29861606
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].
Li PP; Li B; Wang YT; Liu SH; Zhang YN; Zhang R; Bai P; Li XG; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):248-256. PubMed ID: 29747270
[No Abstract] [Full Text] [Related]
20. Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study.
Mahmoud O; Hathout L; Shaaban SG; Elshaikh MA; Beriwal S; Small W
Gynecol Oncol; 2016 Dec; 143(3):539-544. PubMed ID: 27769525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
